Anti-Cyclic Citrullinated Peptide Antibody Is Associated with Interstitial Lung Disease in Patients with Rheumatoid Arthritis

Yin, Yufeng; Liang, Di; Zhao, Lu; Li, Yang; Liu, Wei; Ren, Yan; Li, Yongzhe; Zeng, Xiaofeng; Zhang, Fengchun; Tang, Fu-lin; Shan, Guangliang; Zhang, Xuan

doi:10.1371/journal.pone.0092449

Cited by 58 publications

(54 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum biomarkers have been increasingly investigated for their potential role in identifying RA‐ILD. Protein candidates have included biomarkers widely used in RA (anti‐CCP antibody and RF) , novel autoantibodies (anti–cit‐Hsp90) , cytokines/chemokines (MMP‐7, IP‐10, PARC) , and Sp‐D . Oxidative stress represents a potentially relevant biologic pathway that has not been investigated in prior studies of biomarkers in RA‐ILD.…”

Section: Discussionmentioning

confidence: 99%

Malondialdehyde–Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis–Associated Interstitial Lung Disease

England

Duryee

Roul

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective To compare serum anti–malondialdehyde–acetaldehyde (anti‐MAA) antibody levels and MAA expression in lung tissue from patients with rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) to those found in controls. Methods Anti‐MAA antibody (IgA, IgM, IgG) concentrations were measured in patients with RA‐ILD and compared to those of RA patients with chronic obstructive pulmonary disease (COPD) and RA patients without lung disease. Associations between anti‐MAA antibody with RA‐ILD were assessed using multivariable logistic regression. Lung tissue from patients with RA‐ILD, other ILD, or emphysema, and from controls (n = 3 per group) were stained for MAA, citrulline, macrophages (CD68), T cells (CD3), B cells (CD19/CD27), and extracellular matrix proteins (type II collagen, fibronectin, vimentin). Tissue expression and colocalization with MAA were quantified and compared. Results Among 1,823 RA patients, 90 had prevalent RA‐ILD. Serum IgA and IgM anti‐MAA antibody concentrations were higher in RA‐ILD than in RA with COPD or RA alone (P = 0.005). After adjustment for covariates, the highest quartiles of IgA anti‐MAA antibody concentration (odds ratio 2.09 [95% confidence interval 1.11–3.90]) and IgM (odds ratio 2.23 [95% confidence interval 1.19–4.15]) were significantly associated with the presence of RA‐ILD. MAA expression in RA‐ILD lung tissue was greater than in tissue from all other groups (P < 0.001), and it colocalized with citrulline (r = 0.79), CD19+ B cells (r = 0.78), and extracellular matrix proteins (type II collagen [r = 0.72] and vimentin [r = 0.77]) to the greatest degree in RA‐ILD. Conclusion Serum IgA and IgM anti‐MAA antibody is associated with ILD among RA patients. MAA is highly expressed in RA‐ILD lung tissue, where it colocalizes with other RA autoantigens, autoreactive B cells, and extracellular matrix proteins, highlighting its potential role in the pathogenesis of RA‐ILD.

show abstract

Section: Discussionmentioning

confidence: 99%

Malondialdehyde–Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis–Associated Interstitial Lung Disease

England

Duryee

Roul

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…Poor renal function may contribute to fatal CVD in RA patients (35). Finally, RA patients may have a higher prevalence of unrecognized MI (36) or other silent myocardial damage or lung disease (37)(38)(39) related to systemic inflammation and disease activity (40) that increase mortality independent of CHD and that may also differ by patients' anti-CCP status (37,41).…”

Section: Discussionmentioning

confidence: 99%

Rheumatoid Arthritis, Anti–Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative

Mackey

Kuller

Deane

et al. 2015

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective This report evaluates incidence of cardiovascular disease (CVD) morbidity and mortality over 10 years among the >160,000 postmenopausal women in the Women’s Health Initiative (WHI) in relation to self-reported RA, disease modifying anti-rheumatic drugs (DMARD) use, anti-CCP+, RF+, CVD risk factors, joint pain, and inflammation (white blood cell (WBC) count and IL-6.) Methods Anti-CCP and RF were measured on a sample (n=9,988) of WHI participants with self-reported RA. RA was classified as self-reported RA plus anti-CCP+ positivity and/or use of DMARDs. Self-reported RA that was both anti-CCP− and DMARD− was classified as “unverified RA.” Results Age-adjusted rates of coronary heart disease (CHD), stroke, CVD, fatal CVD and total mortality were higher for women with RA vs. no RA, with multivariable-adjusted HR(95%CI) of 1.46(1.17, 1.83) for CHD, and 2.55(1.86, 3.51) for fatal CVD. Within RA, anti-CCP+ and RF+ were not significantly associated with higher risk of any outcomes, despite slightly higher risk of fatal CVD and death for anti-CCP+ vs. anti-CCP− RA. Joint pain severity and CVD risk factors were strongly associated with CVD risk, even for women with no RA. CVD incidence was increased for RA vs. no RA at almost all risk factor levels, except low levels of joint pain or inflammation. Within RA, inflammation was more strongly associated with fatal CVD and total mortality than CHD or CVD. Conclusion Among postmenopausal women, RA was associated with 1.5-2.5 higher CVD risk, strongly associated with CV risk factors, joint pain severity, and inflammation, but similar for anti-CCP+ and RF+. Clinical Trial Registration clinicaltrials.gov identifier: NCT00000611

show abstract

“…Так, в работе Y. Yin и соавт. [21] обследование 285 больных РА показало отсутствие связи между уровнем РФ и ПЛ. Что касается позитивности по АЦЦП, то наши результаты не позволяют исключить ее из списка факторов риска.…”

Section: Discussionunclassified

Complex Clinical and Instrumental Evaluation of Lung Injury in Patients With Rheumatoid Arthritis

Неcтерович¹,

Ночевная²,

Рабик³

et al. 2016

rsp

View full text Add to dashboard Cite

Anti-Cyclic Citrullinated Peptide Antibody Is Associated with Interstitial Lung Disease in Patients with Rheumatoid Arthritis

Cited by 58 publications

References 33 publications

Malondialdehyde–Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis–Associated Interstitial Lung Disease

Malondialdehyde–Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis–Associated Interstitial Lung Disease

Rheumatoid Arthritis, Anti–Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative

Complex Clinical and Instrumental Evaluation of Lung Injury in Patients With Rheumatoid Arthritis

Contact Info

Product

Resources

About